June 4, 2009 — Takara Bio Inc. (Otsu, Japan) today announced that it has entered into a mutual agreement with Kohjin-bio Co., Ltd (Saitama, Japan) for an alliance in the field of cell culture media. In this alliance, Takara Biomedical Technology (Beijing) Co., Ltd, a subsidiary of Takara Bio, will construct a new factory building on its premises in Beijing. A subsidiary of Kohjin-bio (Beijing, China) will rent a part of this building from Takara Biomedical Technology (Beijing) and will manufacture cell culture media products. The building construction will be completed by March 2010. Takara Bio group will sell the cell culture media products made by the subsidiary of Kohjin-bio exclusively beginning on April, 2010.


Takara Biomedical Technology (Beijing), founded in 2004 as a wholly owned subsidiary of Takara Bio, supports Takara Bio’s clinical development of cancer immunotherapy in China, and also sells Clontech’s research reagents and Takara Bio’s cell culture media in China. As research and development in the field of cell therapy is becoming active in China, the sales of cell culture media in China have expanded significantly.


Takara Bio is aiming to increase sales of cell culture media in China by combining Kojin-bio’s manufacturing technology of cell culture media with Takara Bio’s sales network, and the resulting success will build a solid position in the China market.


In addition to the manufacturing cell culture media products by the subsidiary of Kohjin-bio, manufacturing of Clontech and Takara Bio products will be transferred to Takara Biomedical Technology (Beijing) in order to boost price competitiveness. Takara Biomedical Technology (Beijing) will manufacture cell biology products such as virus vector and antibodies in a new factory building.


[Architectural Overview]

Site area : About 5,300 m2
Total construction cost : About 320 million yen


[ About Takara Bio Inc. ]

Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin® reagent, which is a world-standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology; and is committed preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. More information is available at http://www.takara-bio.com.


[About Kohjin-bio Co., Ltd.]


April 20, 1981

President and CEO

Takahito Nakamura


5-1-3 Chiyoda, Sakado-shi, Saitama 350-0214
Capital 98,000,000 JPY
Employees 70


Animal blood, and serum and a tissue culture medium and raw medical supplies and the culture medium for research Business about manufacture, production of selling laboratory animals, and the export and import of each number before trust of the animal immunity for selling research of a selling medical-implements machine